We are proud to announce launching the DV106 Monkeypox Virus Nucleic Acid Detection Kit (Real-Time PCR)!
What is the Risk of Monkeypox Currently?
Monkeypox is an illness caused by the monkeypox virus. In May 2022, multiple cases of monkeypox are being identified in several non-endemic countries. This is not typical of past patterns of monkeypox. A multi-country outbreak of monkeypox is currently underway in places where the virus has not been typically found before, in Europe, the Americas, Africa, the Western Pacific, and countries of the Eastern Mediterranean. More cases than normal have been reported in 2022 in parts of Africa that have previously reported cases, such as Nigeria, the Democratic Republic of the Congo, and the Central African Republic. WHO is working with all affected countries to enhance surveillance and provide guidance on how to stop the spread and how to care for those infected.[1]
How does Monkeypox Transmit?
Monkeypox virus can be transmitted from person to person through close contact with respiratory secretions of an infected person or animal, skin or mucous membrane lesions, blood, body fluids, or items recently contaminated with body fluids or diseased material of a patient.[2] In addition, the monkeypox virus can also be transmitted through mother-to-child and sexual transmission.
What are the Clinical Symptoms of Monkeypox Virus?
Symptoms of monkeypox virus infection are similar to those of smallpox, but the clinical severity is less severe, with an incubation period of usually 5 to 21 days. The main symptoms are systemic fever, headache, muscle aches or swollen lymph nodes, skin papules, vesicles or pustules, and other pathogenic microorganism infections, lasting 2-5 weeks. And the duration is 2-5 weeks[3].
What is Monkeypox Virus Nucleic Acid Detection Kit (Real-Time PCR)?
This kit is used for in vitro qualitative detection of MPXV in clinical samples such as nasal swabs, oropharyngeal swabs, saliva, urine, skin lesions, exudates, blood and other clinical samples of suspected cases of monkeypox virus (MPXV) infection.
Kit Contents
Component Name | Main Constituents | Specifications (48 tests) | Specifications (200 tests) |
MPXV PCR Reaction Mix | Taq DNA polymerase, uracil-DNA glycosylase, Primers and probes of F3L gene of monkeypox virus and the internal control-RNase P gene, etc. | 960 μL×1 tube | 1000 μL×4 tubes |
MPXV Positive Control | Plasmid with F3L gene of monkeypox virus and the internal control-RNase P gene | 50 μL×1 tube | 200 μL×1 tube |
MPXV Negative Control | RNase-free Water | 50 μL×1 tube | 200 μL×1 tube |
Product Information
Minimum Detection Limit | 500 copies/mL |
Accuracy | Positive Detection Rate | 100% |
Negative Detection Rate for Negative Control | 100% |
Analytical Specificity | No Cross with smallpox virus, vaccinia virus, Treponema pallidum, HIV virus, Epstein-Barr virus, Parvovirus B19, Herpes zoster virus, Influenza A virus (H1N1, H3N2, H5N1, H7N9), Influenza B virus (Yamagata, Victoria), Parainfluenza virus, Mycoplasma pneumoniae, Toxoplasma gondii, Rubella virus, Cytomegalovirus, Herpes simplex virus type II, seven Human coronavirus(SARS-CoV-2, HCoV-HKU1, HCoV-229E, HCoV-OC43, HCoV-NL63, MERS-COV and SARS-COV), Enterovirus virus(EV71,CA16) and Streptococcus pyogenes . |
Precision | Negative detection rate of the negative samples | 100% |
positive detection rate of the strong positive samples | 100% |
positive detection rate of the limited positive samples | ≥95% |
Sample Types | nasal swabs, oropharyngeal swab, saliva, urine, skin lesion tissue, exudate, and blood, etc. |
Storage | -20±5°C away from light for 12 months |
Shipping | Dry ice (-20°C) |
Features
● Simple operation, pre-mixed amplification solution without the need of preparation.
● Multiplex PCR - one single reaction tube per sample. Negative and positive controls are provided for the kit calibration.
● UDG and dUTP minimize carry-over contamination.
● High specificity and sensitivity. No cross-reactivity with the following pathogens: smallpox virus, cowpox virus and vaccinia virus.
● Suitable for FAM and VIC cyclers.
● CE marked.
The product has the Declaration of Conformity in vitro diagnostic medical devices Directive (98/79/EC) IVDD of EU. It indicates that our products meet the requirements of the relevant EU directives, has completed the registration with the EU competent authorities, and meet the access conditions for the EU market.
Reference
[1] WHO, Monkeypox Q&A. 2022 July 12.
[2] Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ. 2020 Sep 1
[3] Eskild P, Anu K, Marion K, Danny A, Adesola Y, Chikwe I, Alimuddin Z. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention, Infectious Disease Clinics of North America, Volume 33, Issue 4, 2019
